Tris Pharma Acquires Pfizer’s NextWave Pharmaceuticals for its Two ADHD Treatments

 Tris Pharma Acquires Pfizer’s NextWave Pharmaceuticals for its Two ADHD Treatments

Tris Pharma Acquires Pfizer’s NextWave Pharmaceuticals for its Two ADHD Treatments

Shots:

  • The acquisition includes NextWave with its two novels ADHD (Attention Deficit Hyperactivity Disorder) treatments, co-developed by NextWave and Tris using Tris’ novel, LiquiXR platform
  • Tris has expanded its ADHD product portfolio with the acquisition of Quillivant XR and QuilliChew ER, which already has Dyanavel XR for ADHD treatment. In 2012, Pfizer acquired NextWave for commercialization of Quillivant XR in North America for ADHD treatment
  • In 2016, Tris launched Dyanavel XR, a liquid amphetamine for children ≥6 years with ADHD. Quillivant XR is extended-release oral liquid methylphenidate, and QuilliChew ER, is an extended-release methylphenidate chewable tablet approved as CNS stimulants for ADHD

Click here to read full press release/ article | Ref: Tris Pharma | Image: PRNewswire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post